Eosinopenia in Severe COPD Exacerbation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age35+
SponsorNorthumbria Healthcare NHS Foundation Trust
About this trial
The goals of this observational study are to identify factors independently associated with admission eosinopenia in patients with a severe exacerbation of chronic obstructive pulmonary disease (COPD) and to determine when blood eosinophil count (BEC) will recover to baseline stable state in patients who are admitted to hospital with a severe exacerbation of COPD and associated eosinopenia.
The main aims of the study are to:
1. Identify demographic, physiological and clinical factors independently associated with admission eosinopenia in patients with a severe exacerbation of COPD 2. Assess the time to recovery from eosinopenia to stable BEC following a severe exacerbation of COPD
Eligibility criteria
Qualifiers
Admitted to hospital with primary clinical diagnosis of exacerbation of COPD*
Smoking history of at least 10 pack years
Airflow obstruction: FEV1/FVC ratio < 0.7 confirmed on historic or inpatient spirometry
Capacity to give informed consent to participate
Disqualifiers
Parasitic infection, systemic fungal infection (excluding infection limited to nails or skin), eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome or other conditions associated with a high eosinophil count#
Active malignancy
Maintenance oral prednisolone or other systemic steroids, anti-interleukin 5 therapy or other medication known to influence eosinophils
Patients with poor venous access
Trial design
Treatments tested in this trial
- Blood eosinophil count
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Northumbria Healthcare NHS Foundation Trust
Lead sponsor
Newcastle University
Collaborator
Chiesi UK
Collaborator
GlaxoSmithKline
Collaborator
Source ClinicalTrials.gov